Skip to main content
SpringerLink
Log in

Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

To assess the validity and reliability of the fatigue subscale of the Functional Assessment of Chronic Illness Therapy (FACIT-F), a 6-item subset from the thrombocytopenia subscale of the Functional Assessment of Cancer Therapy (FACT-Th6) and the Short Form-36 Version 2 (SF-36v2) in 2 clinical trials of the thrombopoietin receptor agonist eltrombopag in chronic immune thrombocytopenia (ITP) patients.

Methods

In the 6-month, RAndomized placebo-controlled ITP Study with Eltrombopag (RAISE; n = 197), the FACIT-F, FACT-Th6, and SF-36v2 were administered at baseline, day 43, weeks 14 and 26, or early withdrawal. In the ongoing open-label extension study, Eltrombopag EXTENDed Dosing Study (EXTEND; n = 154), measures were administered at baseline, at the beginning of each stage, and at permanent discontinuation of study medication.

Results

FACIT-F, FACT-Th6, and SF-36v2 demonstrated acceptable internal consistency reliability (i.e., all Cronbach’s alphas >0.70) and test–retest reliability (all intraclass correlation coefficients >0.70). Construct validity was supported by moderate (0.35 < r < 0.50) to strong (r > 0.50) inter-measure correlations for baseline and change scores. A small to medium magnitude of effect was captured by the FACIT-F and FACT-Th6 among patients who experienced sustained platelet responses.

Conclusions

Results provide support for the validity, reliability, and responsiveness of the FACIT-F, FACT-Th6, and SF-36v2 in chronic ITP patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ANOVA:

Analysis of variance

EXTEND:

Eltrombopag EXTENDed dosing study

FACIT-F:

Fatigue subscale of the Functional Assessment of Chronic Illness Therapy

FACT-Th:

Functional Assessment of Cancer Therapy-Thrombocytopenia

HRQoL:

Health-related quality of life

ICC:

Intraclass correlation coefficient

ITP:

Immune thrombocytopenia

LOTA:

Last on-treatment assessment

MCS:

Mental component summary

MEI-SF:

Motivation and Energy Inventory-Short Form

MID:

Minimally important difference

PCS:

Physical component summary

RAISE:

RAndomized placebo-controlled ITP Study with Eltrombopag

SD:

Standard deviation

SF-36v2:

Medical Outcomes Study Short Form-36 version 2

WHO:

World Health Organization

References

  1. Ballem, P. J., Segal, G. M., Stratton, J. R., Gernsheimer, T., Adamson, J. W., & Slichter, S. J. (1987). Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. The Journal of Clinical Investigation, 80, 33–40.

    Article  PubMed  CAS  Google Scholar 

  2. Chang, M., Nakagawa, P. A., Williams, S. A., Schwartz, M. R., Imfeld, K. L., Buzby, J. S., et al. (2003). Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood, 102, 887–895.

    Article  PubMed  CAS  Google Scholar 

  3. Cines, D. B., & Blanchette, V. S. (2002). Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 995–1008.

    Article  PubMed  Google Scholar 

  4. Feudjo-Tepie, M. A., Robinson, N. J., & Bennett, D. (2008). Prevalence of diagnosed chronic immune thrombocytopenic purpura in the us: Analysis of a large us claim database: A rebuttal. Journal of Thrombosis Haemostasis, 6, 711–712, author reply 713.

    Google Scholar 

  5. Mathias, S. D., Bussel, J. B., George, J. N., McMillan, R., Okano, G. J., & Nichol, J. L. (2007). A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation. Health and Quality of Life Outcomes, 5, 11.

    Article  PubMed  Google Scholar 

  6. Mathias, S. D., Gao, S. K., Miller, K. L., Cella, D., Snyder, C., Turner, R., et al. (2008). Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: A conceptual model starting with the patient perspective. Health and Quality of Life Outcomes, 6, 13. Available at http://www.hqlo.com/content/16/11/13.

  7. Bussel, J. B., Cheng, G., Saleh, M. N., Psaila, B., Kovaleva, L., Meddeb, B., et al. (2007). Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 357, 2237–2247.

    Article  PubMed  CAS  Google Scholar 

  8. Cella, D., Eton, D. T., Lai, J. S., Peterman, A. H., & Merkel, D. E. (2002). Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24, 547–561.

    Article  PubMed  Google Scholar 

  9. Webster, K., Cella, D., & Yost, K. (2003). The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.

    Article  PubMed  Google Scholar 

  10. Cella, D., Beaumont, J. L., Webster, K. A., Lai, J. S., & Elting, L. (2006). Measuring the concerns of cancer patients with low platelet counts: The functional assessment of cancer therapy–thrombocytopenia (FACT-Th) questionnaire. Supportive Care in Cancer, 14, 1220–1231.

    Article  PubMed  Google Scholar 

  11. Ware, J. E., Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Mariush, M. E. (2007). User’s manual for the sf-36v2 health survey (2nd ed.). Lincoln, RI: Quality Metric Incorporated.

  12. Cheng, G., Saleh, M. N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., et al. (2010). Eltrombopag for the long-term management of chronic idiopathic thrombocytopenic purpura: A 6-month, randomized, phase iii study (RAISE). Lancet. Epub ahead of print.

  13. Saleh, M. N., Bussel, J. B., Cheng, G., Meddeb, B., Mayer, B., Bailey, C., et al. (2009). Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: Results from the extend study. Blood, 114, Abstract 682.

  14. Fehnel, S. E., Bann, C. M., Hogue, S. L., Kwong, W. J., & Mahajan, S. S. (2004). The development and psychometric evaluation of the motivation and energy inventory (MEI). Quality of Life Research, 13, 1321–1336.

    Article  PubMed  CAS  Google Scholar 

  15. Marra, C. A., Woolcott, J. C., Kopec, J. A., Shojania, K., Offer, R., Brazier, J. E., et al. (2005). A comparison of generic, indirect utility measures (the hui2, hui3, sf-6d, and the eq-5d) and disease-specific instruments (the raqol and the haq) in rheumatoid arthritis. Social Science and Medicine, 60, 1571–1582.

    Article  PubMed  Google Scholar 

  16. Guttman, L. (1954). Some necessary conditions for common-factor analysis. Psychometrika, 19, 149–161.

    Article  Google Scholar 

  17. Kaiser, H. F. (1960). The application of electronic computers to factor analysis. Educational and Psychological Measurement, 20, 141–151.

    Article  Google Scholar 

  18. Kaiser, H. F. (1961). A note on Guttman’s lower bound for the number of common factors. British Journal of Mathematical and Statistical Psychology, 14, 1.

    Google Scholar 

  19. Kline, P. (1993). Handbook of psychological testing. London: Routledge.

    Google Scholar 

  20. Bland, J. M., & Altman, D. G. (1997). Cronbach’s alpha. British Medical Journal, 314, 572.

    Article  PubMed  CAS  Google Scholar 

  21. Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in addressing rater reliability. Psychological Bulletin, 86, 420–428.

    Article  PubMed  CAS  Google Scholar 

  22. Cohen, J. (1977). Statistical power analysis for the behavioral science (revised ed.) New York: Academic Press.

  23. Moretti, C., Viola, S., Pistorio, A., Magni-Manzoni, S., Ruperto, N., Martini, A., et al. (2005). Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 64, 257–261.

    Article  PubMed  CAS  Google Scholar 

  24. Liang, K.-Y., & Seger, S. L. (1986). Longitudinal data analysis using generalized linear models. Biometrika, 73, 13–22.

    Article  Google Scholar 

  25. Cella, D., Lai, J. S., Chang, C. H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general united states population. Cancer, 94, 528–538.

    Article  PubMed  Google Scholar 

  26. Guyatt, G. H., King, D. R., Feeny, D. H., Stubbing, D., & Goldstein, R. S. (1999). Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. Journal of Clinical Epidemiology, 52(3), 187–92. PubMed PMID: 10210235.

    Google Scholar 

  27. McGraw, K. O., & Wong, S. P. (1996). Forming inferences about some intraclass correlation coefficients. Psychological Methods, 1, 30–46.

    Article  Google Scholar 

Download references

Acknowledgments

Funding for this study was provided by GlaxoSmithKline. All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors. The authors wish to acknowledge the following individuals for their contributions and critical review during the development of this manuscript: Lisa Breck, Steve Collins, and AOI Communications, L.P., for editorial assistance, and Kimberly Marino for critical review.

Author information

Authors and Affiliations

  1. Analysis Group, Inc., Huntington Ave, Boston, MA, USA

    James Signorovitch

  2. GlaxoSmithKline, Global Health Outcomes, Oncology, S Collegeville Rd, Collegeville, PA, USA

    Andres Brainsky & Kelly M. Grotzinger

Authors
  1. James Signorovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andres Brainsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly M. Grotzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelly M. Grotzinger.

Additional information

Trial registration numbers: EXTEND NCT00351468, RAISE NCT00370331.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Signorovitch, J., Brainsky, A. & Grotzinger, K.M. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Qual Life Res 20, 1737–1744 (2011). https://doi.org/10.1007/s11136-011-9912-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-011-9912-9

Keywords

Search

Navigation